Bisphosphonate-related Osteonecrosis of the Jaws: An Update on Clinical, Pathological and Management Aspects

被引：17
作者：
Ficarra G. [1 ,2 ,3 ]
Beninati F. [1 ]
机构：
[1] Reference Center for the Study of Oral Diseases, University of Florence, Florence 50134
[2] Azienda Ospedaliero-Universitaria Careggi, Florence
[3] Department of Odonto-Stomatology, University of Florence, Florence 50134
来源：
Head and Neck Pathology | 2007年 / 1卷 / 2期
关键词：
Bisphosphonate; Bone metastasis; Cancer; Jaws; Osteomyelitis; Osteonecrosis; Osteoporosis; Pamidronate; Review; Zoledronic acid;
D O I：
10.1007/s12105-007-0033-2
中图分类号：
学科分类号：
摘要：
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is mainly observed in patients with multiple myeloma and bone metastasis from solid tumors receiving iv bisphosphonate therapy. The reported incidence of BRONJ is significantly higher with the iv preparations zoledronic acid and pamidronate while the risk appears to be minimal for patients receiving oral bisphosphonates. Currently available published incidence data for BRONJ are based on retrospective studies and estimates of cumulative incidence range from 0.8 to 12%. The mandible is more commonly affected than the maxilla (2:1 ratio), and 60-70% of cases are preceded by a dental surgical procedure. The signs and symptoms that may occur before the appearance of clinical evident osteonecrosis include changes in the health of periodontal tissues, non-healing mucosal ulcers, loose teeth and unexplained soft-tissue infection. Although the definitive role of bisphosphonates remains to be elucidated, the inhibition of physiologic bone remodeling and angiogenesis by these potent drugs impairs the regenerative capacity of the bone causing the development of BRONJ. Tooth extraction as a precipitating event is a common observation. The significant benefits that bisphosphonates offer to patients clearly surpass the risk of potential side effects; however, any patient for whom prolonged bisphosphonate therapy is indicated, should be provided with preventive dental care in order to minimize the risk of developing this severe condition. This article provides an update review of current knowledge about clinical, pathological and management aspects of BRONJ. © Humana Press Inc. 2007.
引用
收藏
页码：132 / 140
页数：8
相关论文
共 64 条
[51]  
Greenspan S.L., Rosen H.N., Parker R.A., Early changes in serum Ntelepeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women, J Clin Endocrinol Metab, 85, pp. 3537-3540, (2000)
[52]  
von Schewelov T., Carlsson A., Dahlberg L., Cross-linked N-telopeptide of type I collagen (NTx) in urine as predictor of periprosthetic osteolysis, J Orthop Res, 24, pp. 1342-1348, (2006)
[53]  
American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonates-related osteonecrosis of the jaws, J Oral Maxillofac Surg, 65, pp. 369-376, (2007)
[54]  
Naveau A., Naveau B., Osteonecrosis of the jaw in patients taking bisphosphonates, Joint Bone Spine, 73, pp. 7-9, (2006)
[55]  
van den Wyngaert T., Manon T.U., Vermorken J.B., Osteonecrosis of the jaw related to use of bisphosphonates, Curr Opin Oncol, 19, pp. 315-322, (2007)
[56]  
Marx R.E., Sawatari Y., Fortin M., Et al., Bisphosphonates-induced exposed bone of the jaws: Risk factors, recognition, prevention, and treatment, J Oral Maxillofac Surg, 63, pp. 1567-1575, (2005)
[57]  
Thakkar S.G., Isada C., Smith J., Et al., Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias, Med Oncol, 23, pp. 51-56, (2006)
[58]  
Pires F.R., Mirando A., Cardoso E.S., Et al., Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy, Oral Dis, 11, pp. 365-369, (2005)
[59]  
Montebugnoli L., Felicetti L., Gissi B., Et al., Bisphosphonateassociated osteonecrosis can be controlled by nonsurgical management, Oral Surg Oral Med Oral Pathol, 104, pp. 473-477, (2007)
[60]  
Adornato M.C., Morcos I., Rozanski J., The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors, J Am Dent Assoc, 138, pp. 971-977, (2007)
1234567